Latest Commercial Partnerships News

1414 Degrees has addressed a sharp rise in its share price and trading volume, attributing the market interest to recent climate policy recommendations and ongoing commercial efforts.

Xamble Group Limited has successfully closed a partially underwritten rights issue, raising approximately A$1.36 million to accelerate its digital marketing platform expansion in Southeast Asia.

Iondrive Limited has inked a binding Term Sheet with Livium Limited to commercialise its innovative Deep Eutectic Solvent (DES) technology for recycling critical materials from batteries, solar panels, and e-waste in Australia, with a pilot plant set to begin commissioning by the end of 2025.

Mesoblast has entered agreements to issue up to US$50 million in convertible notes, aiming to strengthen its capital base and support pipeline growth, pending shareholder approval.

Zeotech Limited has completed its largest commercial concrete demonstration using AusPozz™, a low-carbon metakaolin product that reduces cement content and embodied carbon. The 100 cubic metre pour attracted major industry players and opened doors to new commercial trials and partnerships.

Singular Health Group reported a $6.38 million loss for FY2025 while securing a pivotal $1.3 million commercial agreement with US-based Provider Network Solutions to deploy its 3DICOM software. The company also completed a major cloud migration of its platform, positioning itself for growth in the US healthcare market.

Streamplay Studio Limited reported a remarkable 201% surge in operating revenue for FY25, driven by its strategic acquisition of Noodlecake Studios and expansion into new markets. Despite a wider operating loss, the company achieved positive cash flow and profitability in the final quarter, signaling a promising turnaround.

Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.

Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.

Micro-X reported FY25 revenue of $13.1 million, underpinned by significant US government contracts and pioneering 3D head CT imaging technology, setting the stage for clinical trials and commercial expansion.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.

Biotron Limited reported a significantly reduced net loss of $318,572 for FY2025, bolstered by a $1.27 million capital raise and a $1.81 million R&D tax rebate, as it advances clinical and preclinical antiviral programs.